Serum prostate-specific antigen and prostate volume predict long-term chances in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo
Cg. Roehrborn et al., Serum prostate-specific antigen and prostate volume predict long-term chances in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo, UROLOGY, 54(4), 1999, pp. 662-669
Objectives. To determine whether baseline prostate-specific antigen (PSA),
in addition to prostate volume, is associated with long-term changes in sym
ptoms and urinary flow rate.
Methods. Three thousand forty men with benign prostatic hyperplasia enrolle
d in the PLESS trial were randomly assigned to finasteride 5 mg or placebo
for 4 years. Symptoms and flow rate were assessed every 4 months, and data
were analyzed by dividing the patients into three groups by baseline PSA te
rtiles (0 to 1.3, 1.4 to 3.2, and 3.3 ng/mL or greater) and baseline prosta
te volume tertiles (14 to 41, 42 to 57, and 58 to 150 mL).
Results. After the initial placebo effect, a slow deterioration in symptoms
over time was observed in the placebo-treated men with a baseline PSA 1.4
ng/mL or greater. However, placebo-treated men in the lowest PSA tertile (l
ess than 1.4 ng/mL) had sustained symptomatic improvement that was not seen
in placebo-treated men in the higher tertiles (P <0.001). In all finasteri
de-treated groups, there was initial improvement followed by maintenance or
continued symptom improvement over time (similar to 3 to 3.5 points by the
end of 4 years). The differences in symptom score improvement between plac
ebo and finasteride were marginal for men with baseline PSA levels less tha
n 1.4 ng/mL (P = 0.128) but were highly significant for men with PSA levels
1.4 ng/mL or greater (P <0.001). Urinary flow rate results were similar to
those observed for symptoms. Analysis of symptom and flow rate data by pro
state volume tertiles in a 10% subset of men yielded similar results, namel
y a deterioration of symptoms and flow rate in the two higher tertiles trea
ted with placebo (greater than 41 mt) and a sustained improvement in all th
ree groups of finasteride-treated patients.
Conclusions. Baseline PSA and prostate volume are good predictors of long-t
erm symptomatic and flow rate changes. Baseline PSA levels of 1.4 ng/mL or
greater and enlarged prostate glands predict the best long-term response to
finasteride compared with placebo. UROLOGY 54: 662-669, 1999. (C) 1999, El
sevier Science Inc.